![]() lower viral burden), and less frequently reported any symptoms. A latent class model classified 24% of participants as ‘non-responders’ not developing anti-spike antibodies, who were older, had higher SARS-CoV-2 cycle threshold values during infection (i.e. Here we estimated antibody response after SARS-CoV-2 infection in the general population using representative data from 7,256 United Kingdom COVID-19 infection survey participants who had positive swab SARS-CoV-2 PCR tests from 26-April-2020 to 14-June-2021. And third dose of Sinopharm, if provided may significantly improve spike protein antibody levels.Understanding the trajectory, duration, and determinants of antibody responses after SARS-CoV-2 infection can inform subsequent protection and risk of reinfection, however large-scale representative studies are limited. Based upon the analysis, it can be speculated that two doses of Sinopharm may not be adequate to provide long lasting immunity against SARS-CoV-2. Furthermore, in our future study, we need to follow up the trend and antibody levels for further period of time. Those who received 3 rdĭose had within 3–4 months post second dose had a significant response in spike protein above >250 AU/ml. ![]() The average rate of fall remained 1.71 AU/ml or 1.66 BAU. Few of them got re-infection as well, although good point is that none of them had critical disease or hospitalization and recovered well in few days. It was observed that at 3 rd and 4 th week, most of the patient’s antibody level had fallen to one digit and few were negative. We followed up these subsequently at two to three weeks intervals. The spike protein antibody level reached peak at 3–4 th week after the second dose administration. ![]() Among subjects with previous history of COVID-19 infection the levels of spike protein antibody remained >250 AU/ml post second dose administration. Of note, upon administration of third dose of Sinopharm to a few subjects the spike protein antibody levels were significantly enhanced >250 AU/ml. The average rate of fall of spike protein was approximately 1.71 AU/ml (1.66 BAU) per day. We examined the follow up of the vaccinated group, and found consistent decrease in antibody levels of spike protein of approximately 71.65 AU/ml (69.64 BAU). Interestingly, level of antibody decreased significantly to about 92.2 AU/ml (89.61 BAU). Afterwards, we observed antibody follow up of the vaccinated group of individuals after two weeks. Among the vaccinated subjects, after 1 st dose of administration, on average the spike protein antibody titer was 9.53 AU/ml (9.26 BAU).Īfter administration of booster (second) dose, among majority of individuals the spike protein antibody level was approximately 158.63 AU/ml (154.18 BAU). The anti-Spike protein antibody test was performed on automated analyzer Cobas Modular System 6000 from Roche Diagnostics Germany, with test sensitivity and specificity of 100% and 99.8% respectively. Usually, the antibodies can protect for a few months, however the level of antibodies needs to be monitored so that booster doses could be taken with time. The SARS-CoV-2 has been emerged as serious public health concern ( 7– 10). ![]() Recently, we have also examined strong positive results (85%) with SARS-CoV-2 spike protein antibodies among Sputnik V first dose vaccinated people ( 6). It has been observed that patients got re-infection after recovery from SARS-CoV-2 infection or even after vaccination and possessed low level of spike protein antibody to less than 1–3 U/ml. Cellular immunity is not assessed in laboratory in routine. Spike antibody level depict humoral immunity element of defence. Antibodies level more than 1.5 U/ml is considered to be positive. We aimed to determine the SARS-CoV-2 spike protein antibody levels among 2868 COVID-19 vaccinated group of individuals. The Strategic Advisory Group of Experts on Immunization (SAGE) has recommended Sinopharm vaccine on 2 dose schedule given around 3–4 weeks apart ( 5). For mass vaccination, the Drug Regulatory Authority of Pakistan has approved Sinopharm, CanSinoBIO, Sinovac, AstraZeneca, and Sputnik V ( 4). The phase III clinical trials of the vaccine revealed 79% effectivity however, the interim analysis from UAE showed 86% effectivity of Sinopharm COVID-19 vaccine ( 2– 3). ![]() The China National Pharmaceutical Group Corporation (CNPGC) Sinopharm vaccine is one of two inactivated virus SARS-CoV-2 vaccines ( 1). In global race of synthesizing COVID-19 vaccines, China based biopharmaceutical companies have made huge efforts. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |